Skip to main content
. 2013 Apr 10;67(2):130–140. doi: 10.1016/j.jinf.2013.03.015

Table 3.

Titers of anti-human-coronaviruses antibodies by immunofluorescence and/or neutralization in SARS patients with available paired acute and convalescent serum samples.

HCoV-EMC IF HCoV-EMC NT SARS-CoV IF SARS-CoV NT HCoV-OC43 IF HCoV-229E IF HCoV-NL63 IF
SARS patients with paired sera (n = 4)
Case A (acute) <1:20 <1:10 <1:20 <1:10 1:80 1:80 <1:20
Case A (convalescent) <1:20 <1:10 1:160 1:20 1:160 1:40 <1:20
Case B (acute) 1:20 <1:10 <1:20 <1:10 1:80 1:20 1:40
Case B (convalescent) <1:20 <1:10 1:160 1:160 1:640 1:20 1:20
Case C (acute) <1:20 <1:10 <1:20 <1:10 1:160 1:40 <1:20
Case Ca (convalescent) 1:40 <1:10 1:640 1:80 1:640 1:20 <1:20
Case D (acute) <1:20 <1:10 <1:20 <1:10 1:160 1:20 <1:20
Case Db (convalescent) 1:320 <1:10 1:160 1:80 1:1280 1:80 1:20

IF, immunofluorescence; NT, neutralization.

a

Case C (convalescent) in Table 3 and Case 3 in Table 2 were the same specimens.

b

Case D (convalescent) in Table 3 and Case 17 in Table 2 were the same specimens.